Lantern Pharma Inc. (NASDAQ: LTRN) announced it will host an investor, analyst and shareholder briefing on April 9, 2026, at 8:30 a.m. Eastern, featuring a live demonstration of withZeta.ai, described as the first multi-agentic AI co-scientist for rare cancer drug discovery, development and clinical trial design. The webcast will highlight the platform's capabilities, commercial architecture, competitive positioning and revenue strategy, alongside an overview of the rare cancer market opportunity and Lantern's growth roadmap, with participation from CEO Panna Sharma and Chief Scientific Officer Kishor Bhatia.
Lantern Pharma is an AI-driven company transforming the cost, pace, and timeline of oncology drug discovery and development. The company's proprietary AI and machine learning platform, RADR(R), leverages over 200 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development and generate oncology medicines at dramatically reduced costs and accelerated timelines. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has accelerated the development of its growing pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program.
On average, Lantern's newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2–3 years and at approximately $1.0–2.5 million per program. The company's lead development programs include a Phase 2 clinical program and multiple planned Phase 1b/2a clinical trials. Lantern has also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of its promising therapies for CNS and brain cancers. The company's AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD.
The upcoming demonstration of withZeta.ai represents a significant step in showcasing how multi-agentic AI systems can function as collaborative partners in the scientific process, potentially redefining research and development workflows in the biopharmaceutical industry. For business and technology leaders, this development highlights the accelerating convergence of artificial intelligence and life sciences, where AI platforms are moving beyond analytical tools to become active participants in discovery and design. The implications extend to investment strategies, as companies leveraging such advanced AI architectures may achieve substantial competitive advantages in speed, cost-efficiency, and innovation within high-value markets like rare oncology.
Further details and updates relating to Lantern Pharma are available in the company's newsroom at https://ibn.fm/LTRN. The broader announcement was distributed via AINewsWire, a specialized communications platform focusing on artificial intelligence advancements, which is part of the Dynamic Brand Portfolio at IBN that provides extensive distribution networks and corporate communications solutions. More information about the distribution service is available at https://www.AINewsWire.com.
